The chiastic pattern I’d come to love in Scripture also shows up in God’s design for aging. As a self-professed Bible nerd and a lover of symmetry, no discovery has made me happier than that ...

If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 12.5%, if your total long term capital gain exceeds 1.25 lakh. Any cess/surcharge is not ...

Indian equity indices Sensex and Nifty50 fell sharply on Friday, with major declines in Infosys and Axis Bank shares post their Q3 results. Reliance Industries' shares rose following strong profit ...

Axis Bank shares: The lender reported a 3.8% increase in consolidated net profit for Q3 FY25. The net interest income grew by 9%, and operating profit rose 15%. Despite the positive outcomes, analysts ...

Axis Bank on Thursday (January 16) reported a 3.83% year-on-year rise in net profit, reaching ₹6,304 crore for Q3 FY24-25. This slightly surpassed the ₹6,284 crore estimate from a CNBC-TV18 poll.

Companies that will announce quarterly earnings on January 16 are Alokinds, Axis Bank, Bhansali Engineering Polymers, D B Corp, Decillion Finance, Digicontent, G G Automotive Gears, G G ...

What's so special about Jan. 30 for Vertex? It's the PDUFA action date set by the U.S. Food and Drug Administration (FDA) for making an approval decision on suzetrigine in treating acute pain.

The new underwriting play will be supported by Axis and Hamilton, with a focus on delivering a differentiated product. The product offering will include an app to simplify travel planning ...

Get the Real Story Behind Every Major Earnings Report RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients ...

THE rise of autonomous driving technology puts ride-hailing firms in a dilemma: Adopt the technology now at a high cost for an uncertain payout, or wait and see and risk losing market share. The ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of $520.00. Discover outperforming stocks and invest ...